Clinical Trials

20 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07224672 2026-03-17

ALANIS

60 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07164469 2026-03-11

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

100 enrolled

Hodgkin Disease

NCT05565105 2026-03-03

CD34+ Transplants for Leukemia and Lymphoma

100 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07428993 2026-02-24

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

41 enrolled

Osteosarcoma

NCT07423611 2026-02-20

RACE

388 enrolled

Breast Neoplasms

NCT06594939 2026-02-04

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

31 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07361133 2026-01-22

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

120 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07349771 2026-01-20

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

72 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT07321912 2026-01-08

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

406 enrolled

Sarcoma, Ewing, Osteosarcoma

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

23 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

40 enrolled

Dendritic Cell Sarcoma, Interdigitating

NCT07227584 2025-11-12

ALL Backbone in AYAs

67 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07144657 2025-08-27

GastricMALToma

40 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT07085728 2025-08-22

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

74 enrolled

Plasma cell

Multiple Myeloma

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

134 enrolled

Dendritic Cell Sarcoma, Interdigitating

NCT06921044 2025-04-10

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

33 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06713057 2024-12-03

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

20 enrolled

Head & Neck

Thyroid Neoplasms

NCT06701344 2024-11-22

GOAL

7 enrolled

Enteropathy-Associated T-Cell Lymphoma

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

528 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06470633 2024-06-24

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

29 enrolled

Breast Neoplasms

NCT06404463 2024-05-08

QUEEN-Neo

76 enrolled

Breast Neoplasms

NCT06367114 2024-04-19

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

50 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06238245 2024-02-20

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Other hematologic neoplasm

22 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

182 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05909826 2023-06-18

KMM-KCd

49 enrolled

Plasma cell

Multiple Myeloma

NCT05816694 2023-04-18

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

50 enrolled

Thoracic

Thymoma

NCT05303727 2022-07-01

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

64 enrolled

CNS

Neuroblastoma

NCT05366062 2022-05-13

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

28 enrolled

CNS

Glioma

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

100 enrolled